|Other Names||Kallikrein-9, 3421-, Kallikrein-like protein 3, KLK-L3, KLK9|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6328a was selected from the N-term region of human KLK9. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Tissue Location||Skin, thymus, trachea, cerebellum and spinal cord|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. KLK9 is a novel kallikrein with poptential application for diagnosis, monitoring and therapeutics of various cancers including those of the breast, prostate and testis.
Yousef, G.M., et al., Genomics 65(2):184-194 (2000).Diamandis, E.P., et al., Trends Endocrinol. Metab. 11(2):54-60 (2000).Yousef, G.M., et al., Anticancer Res. 19 (4B), 2843-2852 (1999).Yousef, G.M., et al., Anticancer Res. 79, 2843-2852 (1999).
If you have any additional inquiries please email technical services at email@example.com.